Abstract

Mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) confer resistance to several antimalarial drugs such as chloroquine (CQ) or piperaquine (PPQ), a partner molecule in current artemisinin-based combination therapies. As a member of the Drug/Metabolite Transporter (DMT) superfamily, the vacuolar transporter PfCRT may translocate substrate molecule(s) across the membrane of the digestive vacuole (DV), a lysosome-like organelle. However, the physiological substrate(s), the transport mechanism and the functional regions of PfCRT remain to be fully characterized. Here, we hypothesized that identification of evolutionary conserved sites in a tertiary structural context could help locate putative functional regions of PfCRT. Hence, site-specific substitution rates were estimated over Plasmodium evolution at each amino acid sites, and the PfCRT tertiary structure was predicted in both inward-facing (open-to-vacuole) and occluded states through homology modeling using DMT template structures sharing <15% sequence identity with PfCRT. We found that the vacuolar-half and membrane-spanning domain (and especially the transmembrane helix 9) of PfCRT were more conserved, supporting that its physiological substrate is expelled out of the parasite DV. In the PfCRT occluded state, some evolutionary conserved sites, including positions related to drug resistance mutations, participate in a putative binding pocket located at the core of the PfCRT membrane-spanning domain. Through structural comparison with experimentally-characterized DMT transporters, we identified several conserved PfCRT amino acid sites located in this pocket as robust candidates for mediating substrate transport. Finally, in silico mutagenesis revealed that drug resistance mutations caused drastic changes in the electrostatic potential of the transporter vacuolar entry and pocket, facilitating the escape of protonated CQ and PPQ from the parasite DV.

Highlights

  • Mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) confer resistance to several antimalarial drugs such as chloroquine (CQ) or piperaquine (PPQ), a partner molecule in current artemisinin-based combination therapies

  • All CQ resistance (CQR) haplotypes carry the key K76T mutation that removes a positive charge in transmembrane helices (TMs) 1, suggesting a charge-dependent transport mechanism as CQ is di-protonated in the acidic DV10,13

  • PfCRT remains a protein of utmost clinical importance since both ancient and novel PfCRT mutations are associated with altered in vitro antimalarial activity of some artemisinin-based combination therapies (ACTs) drugs (PPQ, amodiaquine, lumefantrine, and artemisinin derivatives) and with ACT treatment failures[13,16,17,18,19,20,21]

Read more

Summary

Introduction

Mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) confer resistance to several antimalarial drugs such as chloroquine (CQ) or piperaquine (PPQ), a partner molecule in current artemisinin-based combination therapies. PfCRT remains a protein of utmost clinical importance since both ancient and novel PfCRT mutations are associated with altered in vitro antimalarial activity of some ACT drugs (PPQ, amodiaquine, lumefantrine, and artemisinin derivatives) and with ACT treatment failures[13,16,17,18,19,20,21]. For most of these drugs, the PfCRT-dependent pharmaco-modulation might operate through different mechanisms than for CQ19,22,23

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call